Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Renalytix plcRNLX · Entity 7446 | Director · Chief Technical Officer | July 06, 2023 | July 07, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Renalytix plc
Report date July 06, 2023 · Filed July 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Expires 2033-07-05 | Direct | 352,902 |
Reported balance
After 2023-07-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-06 · Grant · Acquired 352,902 · Balance 352,902 F1: The exercise price is 1.025 pounds sterling. The U.S. dollar equivalent of the exercise price is $1.301 using the Bank of England rate as of July 6, 2023 (1.00 pound sterling = $1.269). F2: One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on October 6, 2023, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is 1.025 pounds sterling. The U.S. dollar equivalent of the exercise price is $1.301 using the Bank of England rate as of July 6, 2023 (1.00 pound sterling = $1.269).
F2: One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on October 6, 2023, subject to the Reporting Person's continuous service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2023 Filed Jul 7, 2023 20:25 UTC | Renalytix plc RNLX · Entity 7446 | GrantEmployee Stock Option (right to buy) · Derivative | 352,902 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-041796 · doc4.xml · derivative · entry 1 Fleming Fergus · CIK 0001973429 · Director · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352,902 Underlying: Ordinary Shares · 352,902 shares Expires 2033-07-05 F1 · derivative.exercise_price: The exercise price is 1.025 pounds sterling. The U.S. dollar equivalent of the exercise price is $1.301 using the Bank of England rate as of July 6, 2023 (1.00 pound sterling = $1.269). F2 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on October 6, 2023, subject to the Reporting Person's continuous service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.